tropanes

Summary

Top Publications

  1. ncbi Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD
    Rainard Fuhr
    Early Phase Clinical Unit Berlin, PAREXEL International GmbH, Berlin, Germany
    Chest 141:745-52. 2012
  2. ncbi Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers
    K Lasseter
    Clinical Pharmacology of Miami, Inc, 550 West 84th Street, Miami, FL 33014, USA
    Pulm Pharmacol Ther 25:193-9. 2012
  3. ncbi Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile
    Amadeu Gavaldá
    Almirall, Biology Department, R and D Center, Sant Feliu de Llobregat, Barcelona, Spain
    J Pharmacol Exp Ther 331:740-51. 2009
  4. ncbi Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD
    Francois Maltais
    Centre de Recherche, Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Universite Laval, 2725 Chemin Sainte Foy, Quebec G1V 4G5, Canada
    Respir Med 105:580-7. 2011
  5. ncbi Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD
    Jørgen Vestbo
    Manchester Academic Health Sciences Centre, UK
    COPD 7:331-6. 2010
  6. ncbi Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects
    Yi Hsin Weng
    Movement Disorders Unit, The First Department of Neurology, Chang Gung Memorial Hospital and Medical College, Taipei, Taiwan
    J Nucl Med 45:393-401. 2004
  7. pmc Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease
    Paul W Jones
    St George s, University of London, London, UK
    Respir Res 12:55. 2011
  8. ncbi Evidence that biosynthesis of the neurotoxic alkaloids anatoxin-a and homoanatoxin-a in the cyanobacterium Oscillatoria PCC 6506 occurs on a modular polyketide synthase initiated by L-proline
    Annick Méjean
    Laboratoire de Biochimie des Microorganismes Enzymologie, Métabolisme et Antibiotiques UMR CNRS 7223, ENSCP, 11 rue Pierre et Marie Curie, 75231 Paris Cedex 05, France
    J Am Chem Soc 131:7512-3. 2009
  9. ncbi First report of (homo)anatoxin-a and dog neurotoxicosis after ingestion of benthic cyanobacteria in The Netherlands
    Elisabeth J Faassen
    Aquatic Ecology and Water Quality Management Group, Wageningen University, P O Box 47, 6700 DD Wageningen, The Netherlands
    Toxicon 60:378-84. 2012
  10. ncbi Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling
    Roberto Cilia
    Toronto Western Research Institute and Hospital, UHN, University of Toronto, Ontario, Canada
    Neurobiol Dis 39:98-104. 2010

Detail Information

Publications209 found, 100 shown here

  1. ncbi Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD
    Rainard Fuhr
    Early Phase Clinical Unit Berlin, PAREXEL International GmbH, Berlin, Germany
    Chest 141:745-52. 2012
    ..The efficacy and safety of aclidinium bromide bid, a novel, long-acting, muscarinic antagonist, was assessed in patients with moderate to severe COPD...
  2. ncbi Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers
    K Lasseter
    Clinical Pharmacology of Miami, Inc, 550 West 84th Street, Miami, FL 33014, USA
    Pulm Pharmacol Ther 25:193-9. 2012
    ..Aclidinium bromide exhibited time-independent PK following dosing to steady state, indicating that similar concentration versus time profiles will occur after repeated administration at the same dose and frequency...
  3. ncbi Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile
    Amadeu Gavaldá
    Almirall, Biology Department, R and D Center, Sant Feliu de Llobregat, Barcelona, Spain
    J Pharmacol Exp Ther 331:740-51. 2009
    ..2 versus 1.6). These results indicate that aclidinium is a potent muscarinic antagonist with a fast onset of action, a long duration of effect, and a favorable cardiovascular safety profile...
  4. ncbi Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD
    Francois Maltais
    Centre de Recherche, Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Universite Laval, 2725 Chemin Sainte Foy, Quebec G1V 4G5, Canada
    Respir Med 105:580-7. 2011
    ..Static and dynamic lung hyperinflation are associated with exercise impairment and poor outcomes in COPD patients. Aclidinium bromide is a novel, long-acting inhaled muscarinic antagonist currently in development for COPD treatment...
  5. ncbi Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD
    Jørgen Vestbo
    Manchester Academic Health Sciences Centre, UK
    COPD 7:331-6. 2010
    ..In conclusion, aclidinium provided effective bronchodilation, similar to that seen with tiotropium, with significant improvements compared with placebo observed from 10 minutes post-dose...
  6. ncbi Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects
    Yi Hsin Weng
    Movement Disorders Unit, The First Department of Neurology, Chang Gung Memorial Hospital and Medical College, Taipei, Taiwan
    J Nucl Med 45:393-401. 2004
    ....
  7. pmc Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease
    Paul W Jones
    St George s, University of London, London, UK
    Respir Res 12:55. 2011
    ..The long-term efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist, were investigated in patients with moderate to severe chronic obstructive pulmonary disease (COPD)...
  8. ncbi Evidence that biosynthesis of the neurotoxic alkaloids anatoxin-a and homoanatoxin-a in the cyanobacterium Oscillatoria PCC 6506 occurs on a modular polyketide synthase initiated by L-proline
    Annick Méjean
    Laboratoire de Biochimie des Microorganismes Enzymologie, Métabolisme et Antibiotiques UMR CNRS 7223, ENSCP, 11 rue Pierre et Marie Curie, 75231 Paris Cedex 05, France
    J Am Chem Soc 131:7512-3. 2009
    ..All of these data provide strong evidence that we have successfully identified the gene cluster responsible for the production of anatoxin-a and homoanatoxin-a in Oscillatoria PCC 6506...
  9. ncbi First report of (homo)anatoxin-a and dog neurotoxicosis after ingestion of benthic cyanobacteria in The Netherlands
    Elisabeth J Faassen
    Aquatic Ecology and Water Quality Management Group, Wageningen University, P O Box 47, 6700 DD Wageningen, The Netherlands
    Toxicon 60:378-84. 2012
    ..Dutch recreational waters are at this moment only screened for pelagic cyanobacterial species, the current bathing water protocol therefore does not protect humans and animals from negative effects of blooms of benthic cyanobacteria...
  10. ncbi Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling
    Roberto Cilia
    Toronto Western Research Institute and Hospital, UHN, University of Toronto, Ontario, Canada
    Neurobiol Dis 39:98-104. 2010
    ..The latter hypothesis is most likely given that the functional reduction of presynaptic reuptake would be more consistent with the increased dopamine levels in the ventral striatum recently reported in PD gamblers...
  11. ncbi Imaging essential tremor
    Ioannis U Isaias
    Department of Human Physiology, University of Milano, Milano, Italy
    Mov Disord 25:679-86. 2010
    ..In conclusion, PD and ET do not share a common pattern of dopaminergic loss over time. However, mild impairment of dopamine transporter in the caudate nucleus may contribute to tremor onset in ET...
  12. ncbi Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients
    M Plotkin
    Klinik fur Strahlenheilkunde, Campus Virchow Klinikum, Charite Universitatsmedizin, Berlin, Germany
    J Neural Transm 112:677-92. 2005
    ..IBZM SPECT is useful to approve the diagnosis of PSP and MSA although a normal finding cannot exclude an atypical PS. IBZM SPECT seems to be of restricted value in CBD...
  13. ncbi Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial
    Karin Schmid
    APEX GmbH, Munich, Germany
    Clin Ther 32:1798-812. 2010
    ..Aclidinium bromide is an inhaled, long-acting muscarinic antagonist currently in development for the treatment of chronic obstructive pulmonary disease. Renal impairment may affect drug clearance...
  14. ncbi Immunolocalisation of two tropinone reductases in potato (Solanum tuberosum L.) root, stolon, and tuber sprouts
    Heike Kaiser
    Institute of Pharmaceutical Biology and Pharmacology, Martin Luther University Halle Wittenberg, Hoher Weg 8, 06120 Halle Saale, Germany
    Planta 225:127-37. 2006
    ..Cortex cells of root and stolon contained the protein; additional strong immuno-labelling was located in phloem parenchyma. In tuber spouts, however, the protein was detected in companion cells...
  15. ncbi 99mTc-TRODAT-1 SPECT in healthy and 6-OHDA lesioned parkinsonian monkeys: comparison with 18F-FDOPA PET
    W S Huang
    Department of Nuclear Medicine, National Defense Medical Center, Tri Service General Hospital, Taipei, Taiwan
    Nucl Med Commun 24:77-83. 2003
    ..In conclusion, our data in a limited series of cases indicate that 99Tc-TRODAT-1 with a conventional nuclear medicine camera system may provide a suitable tool in evaluating parkinsonism in a primate model...
  16. ncbi The functional divergence of short-chain dehydrogenases involved in tropinone reduction
    Andrea Brock
    Institute of Pharmacy, Faculty of Science I, Martin Luther University Halle Wittenberg, Hoher Weg 8, D 06120 Halle Saale, Germany
    Plant J 54:388-401. 2008
    ..Thus C. officinalis TR presents an example of an enzyme with relaxed substrate specificity, like short-chain dehydrogenases, that provides favorable preconditions for the evolution of novel functions in biosynthetic sequences...
  17. ncbi In-vivo quantification of dose-dependent dopamine transporter blockade in the rat striatum with small animal SPECT
    Susanne Nikolaus
    Clinic of Nuclear Medicine, University Hospital Dusseldorf, Germany
    Nucl Med Commun 28:207-13. 2007
    ..This study investigated dopamine transporter blockade in the rat striatum after treatment with various doses of methylphenidate using a high-resolution small animal SPECT ('TierSPECT') and I-FP-CIT...
  18. ncbi Molecular cloning and catalytic characterization of a recombinant tropine biosynthetic tropinone reductase from Withania coagulans leaf
    Amit K Kushwaha
    Central Institute of Medicinal and Aromatic Plants CSIR, Kuckrail Picnic Spot Road, P O CIMAP, Lucknow 226015, India
    Gene 516:238-47. 2013
    ..To our knowledge, this pertains to be the first report on any gene and enzyme of secondary metabolism from the commercially and medicinally important vegetable rennet species...
  19. ncbi First report in a river in France of the benthic cyanobacterium Phormidium favosum producing anatoxin-a associated with dog neurotoxicosis
    Muriel Gugger
    USM0505 Ecosystèmes et interactions toxiques, M N H N, Paris, France
    Toxicon 45:919-28. 2005
    ..Finally, several cyanobacterial strains were isolated from the green biofilm and tested for anatoxin-a production. Phormidium favosum was identified as a new anatoxin-a producing species...
  20. pmc Crystal structures of two tropinone reductases: different reaction stereospecificities in the same protein fold
    K Nakajima
    Graduate School of Biological Sciences, Nara Institute of Science and Technology, Ikoma, Nara 630 0101, Japan
    Proc Natl Acad Sci U S A 95:4876-81. 1998
    ..The results obtained herein raise the possibility that in certain cases different stereospecificities can be acquired in enzymes by changing a few amino acid residues within substrate binding sites...
  21. ncbi Pharmacological challenge and synaptic response - assessing dopaminergic function in the rat striatum with small animal single-photon emission computed tomography (SPECT) and positron emission tomography (PET)
    Susanne Nikolaus
    Clinic of Nuclear Medicine, University Hospital Dusseldorf, Moorenstr 5, D 40225 Dusseldorf, Germany
    Rev Neurosci 22:625-45. 2011
    ..This pertains to animal models of diseases associated with pre- or postsynaptic DAergic deficiencies such as Parkinson's disease, Huntington's disease, attention-deficit/hyperactivity disorder, schizophrenia or drug abuse...
  22. ncbi Calystegine distribution in some solanaceous species
    K Bekkouche
    Laboratory of Medicinal Plants and Phytochemistry, Department of Biology, Faculty of Sciences-Semlalia, PO Box 2390, Marrakech, Morocco
    Phytochemistry 58:455-62. 2001
    ..In all the investigated samples, calystegines A(5) and B(4) were never detected. This report focuses for the first time on calystegines in Withania and Brunfelsia genera and in Mandragora autumnalis and Solanum sodomaeum species...
  23. pmc Investigating the role of 99mTc-TRODAT-1 SPECT imaging in idiopathic Parkinson's disease
    Yu Geng
    Department of Neurology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China
    J Zhejiang Univ Sci B 6:22-7. 2005
    ..To investigate the role of 99mTc-TRODAT-1 SPECT in diagnosis and assessing severity of idiopathic Parkinson's disease (PD)...
  24. ncbi Molecular characterization of planktic cyanobacteria of Anabaena, Aphanizomenon, Microcystis and Planktothrix genera
    C Lyra
    Department of Applied Chemistry and Microbiology, Helsinki University, Finland
    Int J Syst Evol Microbiol 51:513-26. 2001
    ..The three other clades contained (ii) filamentous non-heterocystous Planktothrix, (iii) unicellular non-heterocystous Microcystis and (iv) Synechococcus strains...
  25. pmc Anatoxin-a synthetase gene cluster of the cyanobacterium Anabaena sp. strain 37 and molecular methods to detect potential producers
    Anne Rantala-Ylinen
    Department of Food and Environmental Microbiology, Division of Microbiology, P O Box 56 Viikinkaari 9, FI 00014 University of Helsinki, Finland
    Appl Environ Microbiol 77:7271-8. 2011
    ....
  26. ncbi Diagnostic accuracy of [99mTc]TRODAT-1 SPECT imaging in early Parkinson's disease
    K L Chou
    Parkinson s Disease and Movement Disorders Center, University of Pennsylvania School of Medicine, Pennsylvania Hospital, 330 South Ninth Street, Philadelphia, PA 19107, USA
    Parkinsonism Relat Disord 10:375-9. 2004
    ..79, specificity 0.92). These findings show that TRODAT imaging can accurately differentiate early PD patients from controls and has the potential to improve the diagnosis of patients with early signs of PD...
  27. pmc Dopamine transporter levels in cocaine dependent subjects
    Paul Crits-Christoph
    Department of Psychiatry, University of Pennsylvania, 3535 Market Street, Suite 650, Philadelphia, PA 19104, USA
    Drug Alcohol Depend 98:70-6. 2008
    ..DAT levels were unrelated to craving, severity of cocaine use, or duration of cocaine use, but DAT levels in the caudate and anterior putamen were significantly (p<0.05) negatively correlated with days since last use of cocaine...
  28. ncbi First report of anatoxin-a-producing cyanobacterium Aphanizomenon issatschenkoi in northeastern Germany
    Andreas Ballot
    Leibniz Institute of Freshwater Ecology and Inland Fisheries, Department of Limnology of Stratified Lakes, Alte Fischerhütte 2, 16775 Stechlin, Germany
    Toxicon 56:964-71. 2010
    ..Anabaena spp. and Anabaenopsis spp. strains from lakes Stolpsee, Langersee, Melangsee, and Scharmützelsee. This study is the first confirming A. issatschenkoi as an ATX producer in German water bodies...
  29. ncbi The effect of levodopa therapy on dopamine transporter SPECT imaging with( 123)I-FP-CIT in patients with Parkinson's disease
    Orazio Schillaci
    Department of Biopathology and Diagnostic Imaging, University Tor Vergata, Rome, Italy
    Eur J Nucl Med Mol Imaging 32:1452-6. 2005
    ..The aim of this study was to evaluate, by means of (123)I-FP-CIT SPECT, the effect of chronic treatment with levodopa on striatal dopamine transporter (DAT) in patients with Parkinson's disease...
  30. pmc Different genotypes of anatoxin-producing cyanobacteria coexist in the Tarn River, France
    Sabrina Cadel-Six
    Unité des Cyanobactéries CNRS URA 2172, Institut Pasteur, 28 rue du Docteur Roux, 75724 Paris Cedex 15, France
    Appl Environ Microbiol 73:7605-14. 2007
    ..Furthermore, they reemphasize the importance of monitoring benthic cyanobacteria in aquatic environments to fully assess the health risks associated with these organisms...
  31. ncbi Aclidinium inhibits cholinergic and tobacco smoke-induced MUC5AC in human airways
    J Cortijo
    Clinical PharmacologyFaculty of Medicine of the University of Valencia, Research Foundation of University Clinic Hospital, Valencia, Spain
    Eur Respir J 37:244-54. 2011
    ..This effect may contribute to the clinical efficacy of aclidinium in mucus hypersecretory diseases including COPD...
  32. ncbi Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging
    W S Huang
    Department of Nuclear Medicine, National Defense Medical Center, Tri-Service General Hospital, Taipei, Taiwan
    J Nucl Med 42:1303-8. 2001
    ..CONCLUSION: For clinical practice, 99mTc-TRODAT-1 may serve as a useful imaging agent for the early detection of Parkinson's disease...
  33. ncbi Effects of elicitors on tropane alkaloids and gene expression in Atropa baetica transgenic hairy roots
    Nabil El Jaber-Vazdekis
    Instituto Universitario de Bio Orgánica AG González, University of La Laguna, 38206 La Laguna, Tenerife, Spain
    J Nat Prod 71:2026-31. 2008
    ....
  34. ncbi Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs
    Jan Booij
    Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 35:424-38. 2008
    ..Moreover, in preclinical studies, animals will be anesthetized. Prescribed drugs, drugs of abuse, and anesthetics may influence the visual interpretation and/or quantification of [(123)I]FP-CIT SPECT scans...
  35. ncbi Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler
    S P Newman
    Pharmaceutical Profiles Ltd, Nottingham, UK
    Respiration 78:322-8. 2009
    ..A next-generation multidose dry powder inhaler will be used for the delivery of aclidinium bromide...
  36. ncbi Induction of tropane alkaloid formation in transformed root cultures of Brugmansia suaveolens (Solanaceae)
    Rawia Zayed
    Institut für Pharmazie und molekulare Biotechnologie, Universitat Heidelberg, INF 364, D 69120 Heidelberg, Germany
    Z Naturforsch C 59:863-7. 2004
    ..Quercetin enhanced the alkaloid production 10 fold (0.4 mg/g fresh weight) within 24 h. In contrast 100 microM salicylic acid decreased alkaloids to a level of 1 microg/g fresh weight...
  37. ncbi Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants
    Josep M Jansat
    Laboratorios Almirall, SA, Barcelona, Spain
    J Clin Pharmacol 49:1239-46. 2009
    ..These data suggest a low systemic bioavailability and favorable safety profile for aclidinium bromide with repeated dosing for COPD...
  38. pmc Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study
    Vanessa J Schelfhout
    Department of Respiratory Medicine, Ghent University Hospital, De Pintelaan 185, B9000, Ghent, Belgium
    Br J Clin Pharmacol 69:458-64. 2010
    ..This phase I trial in healthy subjects investigated the bronchodilator activity of aclidinium and its ability to reduce methacholine-induced bronchoconstriction...
  39. ncbi Aclidinium bromide abrogates allergen-induced hyperresponsiveness and reduces eosinophilia in murine model of airway inflammation
    Gautam Damera
    Airways Biology Initiative, Pulmonary, Allergy and Critical Care Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States
    Eur J Pharmacol 649:349-53. 2010
    ..These data suggest that aclidinium, a selective muscarinic antagonist, not only acts as a bronchodilator but could also act as an anti-inflammatory agent with potential clinical benefits in the treatment of COPD and asthma...
  40. ncbi Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide
    Joan Alberti
    Department of Pharmacokinetics and Drug Metabolism, Almirall, S A, 08980 Sant Feliu de Llobregat, Barcelona, Spain
    Drug Metab Dispos 38:1202-10. 2010
    ..These results suggest that the potential for clinical interactions involving human cholinesterases is remote at clinically relevant plasma, which are less than 1 nM...
  41. ncbi Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites
    Sonia Sentellas
    Almirall, R and D Center, Sant Feliu de Llobregat, Barcelona, Spain
    Eur J Pharm Sci 39:283-90. 2010
    ..These results suggest that aclidinium may have a reduced systemic exposure and therefore less propensity for class-related systemic side effects in the clinical setting...
  42. ncbi Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients
    G F Joos
    Department of Respiratory Medicine, Ghent University Hospital, De Pintelaan 185, B9000 Ghent, Belgium
    Respir Med 104:865-72. 2010
    ..This study evaluated the pharmacodynamics, pharmacokinetics, safety and tolerability of ascending doses of aclidinium bromide in patients with COPD...
  43. ncbi Molecular cloning and characterization of two tropinone reductases in Anisodus acutangulus and enhancement of tropane alkaloid production in AaTRI-transformed hairy roots
    Guoyin Kai
    Laboratory of Plant Biotechnology, College of Life and Environment Sciences, Shanghai Normal University, 100 Guilin Road, Shanghai 200234, People s Republic of China
    Biotechnol Appl Biochem 54:177-86. 2009
    ..87-fold higher level of hyoscyamine and a mean 8-fold higher level of scopolamine compared with control roots, indicating that AaTRI is a promising target for genetic engineering to increase tropane alkaloid in A. acutangulus...
  44. ncbi Aclidinium bromide provides long-acting bronchodilation in patients with COPD
    P Chanez
    Universite de la Mediterranee, Departement des Maladies Respiratoires, AP HM, 270 Boulevard de Sainte Marguerite, F 13009 Marseille, France
    Pulm Pharmacol Ther 23:15-21. 2010
    ..Aclidinium produced sustained bronchodilation over 24h and was well tolerated during this short-term study. Based on these data, aclidinium 200microg was selected as the investigational dose for future clinical trials in COPD...
  45. ncbi Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD
    H Magnussen
    Pulmonary Research Institute, Hospital Grosshansdorf, Center for Pneumology and Thoracic Surgery, Woehrendamm 80, 22927 Grosshansdorf, Germany
    Respir Med 103:1832-7. 2009
    ..In conclusion, patients with moderate or severe COPD were able to generate sufficient inspiratory airflow through the Genuair inhaler to reliably inhale the full dose and reset the inhaler...
  46. ncbi [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease
    A Siderowf
    Parkinson Disease and Movement Disorders Center, Department of Neurology, University of Pennsylvania, Philadelphia, USA
    Neurology 64:1716-20. 2005
    ..In vivo imaging of the dopamine transporter with [99mTc]TRODAT-1 (TRODAT) and olfactory testing have both been proposed as potential biomarkers in Parkinson disease (PD)...
  47. ncbi Dopamine transporter gene polymorphism, spect imaging, and levodopa response in patients with Parkinson disease
    Manuela Contin
    Neurology Clinic, Department of Neurological Sciences, University of Bologna, Italy
    Clin Neuropharmacol 27:111-5. 2004
    ....
  48. pmc Engineering tropane biosynthetic pathway in Hyoscyamus niger hairy root cultures
    Lei Zhang
    State Key Laboratory of Genetic Engineering, Morgan Tan International Center for Life Sciences, School of Life Sciences, Fudan University, Shanghai 200433, China
    Proc Natl Acad Sci U S A 101:6786-91. 2004
    ..niger whereas the functioning of the upstream enzyme PMT is increased proportionally. This study provides an effective approach for large-scale commercial production of scopolamine by using hairy root culture systems as bioreactors...
  49. ncbi An update on the efficacy and safety of aclidinium bromide in patients with COPD
    Khuder Alagha
    Respiratory Department, AP HM, Inserm CNRS U 600, UMR6212, Universite de la Mediterranee, 13009 Marseille, France
    Ther Adv Respir Dis 5:19-28. 2011
    ..Aclidinium is now moving to phase III clinical development for chronic obstructive pulmonary disease (COPD)...
  50. ncbi Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects
    Kenneth C Lasseter
    Clinical Pharmacology of Miami, 550 West 84th Street, Miami, FL 33014, USA
    J Clin Pharmacol 51:923-32. 2011
    ..It is concluded that aclidinium bromide, at doses up to 800 µg, has a favorable cardiovascular safety profile with no effect on QT interval...
  51. ncbi Studies of selected phenyltropanes at monoamine transporters
    M J Kuhar
    Division of Neuroscience, Yerkes Regional Primate Research Center of Emory University, Atlanta, GA 30322, USA
    Drug Alcohol Depend 56:9-15. 1999
    ....
  52. ncbi [3H]MFZ 2-12: a novel radioligand for the dopamine transporter
    A H Newman
    Medicinal Chemistry Section, National Institute on Drug Abuse Intramural Research Program, 5500Nathan Shock Drive, MD 21224, Baltimore, USA
    Bioorg Med Chem Lett 11:1659-61. 2001
    ..The N-nor-intermediate (MFZ 2-13) was treated with CT(3)I resulting in [(3)H]MFZ 2-12; S.A.=80 Ci/mmol). [(3)H]MFZ 2-12 reversibly bound with a K(D) of 2.8nM to human dopamine transporter expressed heterologously in EM4 cells...
  53. ncbi Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects
    J M Jansat
    Laboratorios Almirall, SA, Barcelona, Spain
    Int J Clin Pharmacol Ther 47:460-8. 2009
    ..The objective of this Phase I study was to determine the maximum tolerated dose (MTD) as well as the tolerability, safety and pharmacokinetics of aclidinium in healthy subjects...
  54. ncbi Parametric mapping of [18F]FPCIT binding in early stage Parkinson's disease: a PET study
    Y Ma
    Center for Neurosciences, North Shore Long Island Jewish Research Institute, Functional Brain Imaging Laboratory, North Shore University Hospital, New York University School of Medicine, Manhasset, New York 11030, USA
    Synapse 45:125-33. 2002
    ..This method provides a useful tool to track the onset and progression of PD at its earliest stages...
  55. ncbi An extended study of dimeric phenyl tropanes
    Susan Nielsen
    Department of Chemistry, Aarhus University, Langelandsgade 140, DK 8000 Aarhus C, Denmark
    Bioorg Med Chem 17:4900-9. 2009
    A series of dimeric phenyl tropanes consisting of two molecules of 4-chloro, 4-iodo or 4-(3-thiopheno)-phenyl tropane tethered together at the carboxylic acid moiety by a diamine or diol linker were prepared...
  56. ncbi Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)ace
    Maria Prat
    Almirall, R and D Centre, Sant Feliu de Llobregat, Barcelona, Spain
    J Med Chem 52:5076-92. 2009
    ..Aclidinium bromide is currently in phase III development for maintenance treatment of patients with COPD...
  57. ncbi Fine-scale spatial variability in anatoxin-a and homoanatoxin-a concentrations in benthic cyanobacterial mats: implication for monitoring and management
    S A Wood
    Cawthron Institute, Nelson, New Zealand
    J Appl Microbiol 109:2011-8. 2010
    ....
  58. ncbi Effect of pmt gene overexpression on tropane alkaloid production in transformed root cultures of Datura metel and Hyoscyamus muticus
    Elisabet Moyano
    Departament de Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra, Avda Dr Aiguader 80, E 08003 Barcelona, Spain
    J Exp Bot 54:203-11. 2003
    ..The results indicate that the same biosynthetic pathway in two related plant species can be differently regulated, and overexpression of a given gene does not necessarily lead to a similar accumulation pattern of secondary metabolites...
  59. ncbi Rhodamine-labeled 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)tropane analogues as high-affinity fluorescent probes for the dopamine transporter
    Joo Hwan Cha
    Medicinal Chemistry Section, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, Maryland 21224, USA
    J Med Chem 48:7513-6. 2005
    ..Visualization of the DAT with 5 and 9 was demonstrated by confocal fluorescence laser scanning microscopy in stably transfected HEK293 cells...
  60. ncbi [Application of 123I-FP-CIT in the clinical practice in Parkinsonism patients]
    S J Ortega Lozano
    Servicio de Medicina Nuclear, Hospital Universitario Virgen de la Victoria, Malaga, Spain
    Rev Esp Med Nucl 24:224-33. 2005
    ..The objective of this study is to perform a descriptive analysis of the main diagnostic aspects obtained from the first 110 studies made with FP-CIT in our center...
  61. ncbi Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease
    A Varrone
    Biostructure and Bioimaging Institute, National Research Council, Via S Pansini, 5, 80131, Napoli, Italy
    Neurology 63:2097-103. 2004
    ..To investigate whether the presence of parkin gene mutations is associated with different nigrostriatal impairment than other early-onset parkinsonism...
  62. ncbi Dopamine transporter density may be associated with the depressed affect in healthy subjects
    Andrew Newberg
    Department of Radiology, Division of Nuclear Medicine, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Nucl Med Commun 28:3-6. 2007
    ..We used the selective DAT radiopharmaceutical Tc-TRODAT-1 and SPECT brain imaging, to examine differences in DAT levels in healthy subjects with and without depressive affect...
  63. ncbi Reproducibility of dopamine transporter density measured with 123I-FPCIT SPECT in normal control and Parkinson's disease patients
    Tatsuro Tsuchida
    Department of Medical Imaging, Mount Sinai Hospital, USA
    Ann Nucl Med 18:609-16. 2004
    ..The objective of this study was to evaluate the reproducibility of 123I-FPCIT SPECT by using whole striatal region of interest (ROI) and subdivided ROI in normal controls (NC) and Parkinson's disease (PD) patients...
  64. ncbi The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate
    Keun Ah Cheon
    Department of Psychiatry, College of Medicine, Kwandong University, Myong Ji Hospital, 697 24 Hwajung dong, Dukyang ku 412 270, Koyang, Kyunggi Do, Republic of Korea
    Eur Neuropsychopharmacol 15:95-101. 2005
    ..Our findings support an association between homozygosity for 10-repeat allele at DAT1 and the DAT density assessed in vivo and correlation between the homozygosity for 10-repeat allele and poor response to MPH...
  65. ncbi Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT
    K Stiasny-Kolster
    Department of Neurology, Center of Nervous Diseases, Philipps University of Marburg, Germany
    Brain 128:126-37. 2005
    ..Since narcoleptic patients are not known to have an increased risk of developing parkinsonism, the pathophysiology and clinical relevance of hyposmia in RBD/narcolepsy patients requires further research...
  66. ncbi Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Nucl Med 46:227-32. 2005
    ..We studied the correlation of striatal dopamine transporter (DAT) imaging with anxiety and depression symptoms in Parkinson's disease (PD)...
  67. ncbi [Change of dopamine transporter activity (DAT) during the action of bupropion (in depression)]
    Zoltan Szabo
    Szegedi Tudomanyegyetem, Pszichiatriai Klinika
    Neuropsychopharmacol Hung 6:79-81. 2004
    ..The average occupancy of bupropion on DAT was similar to the international findings at 20.84% in 9 depressed patients...
  68. ncbi Absolute quantification in dopaminergic neurotransmission SPECT using a Monte Carlo-based scatter correction and fully 3-dimensional reconstruction
    Albert Cot
    Unitat de Biofisica i Bioenginyeria, Departament Ciències Fisiològiques I, Facultat de Medicina, Universitat de Barcelona, Spain
    J Nucl Med 46:1497-504. 2005
    ..This work is focused on assessment of the quantification of specific uptake of (99m)Tc-DAT ligands when compensation for all degrading phenomena is performed...
  69. ncbi Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies
    Walter Koch
    Department of Nuclear Medicine, University of Munich, Munich, Germany
    J Nucl Med 46:1109-18. 2005
    ....
  70. ncbi Pilot study on the effect of estrogen replacement therapy on brain dopamine transporter availability in healthy, postmenopausal women
    Sara A Gardiner
    ePharmaLearning, Inc
    Am J Geriatr Psychiatry 12:621-30. 2004
    ..Authors investigated the association between estrogen replacement therapy (ERT) and dopamine transporter (DAT) availability in women...
  71. ncbi Do dopamine agonists or levodopa modify Parkinson's disease progression?
    K Marek
    The Institute for Neurodegenerative Disorders, New Haven, CT 06510, USA
    Eur J Neurol 9:15-22. 2002
    ..These data highlight the need to compare imaging outcomes of dopamine neuronal loss with multiple meaningful clinical endpoints of disease progression in placebo controlled, larger and long-term studies...
  72. ncbi Synthesis and pharmacology of 6-substituted benztropines: discovery of novel dopamine uptake inhibitors possessing low binding affinity to the dopamine transporter
    Daniele Simoni
    Dipartimento di Scienze Farmaceutiche, Universita di Ferrara, Via Fossato di Mortara 17 19, 44100 Ferrara, Italy
    J Med Chem 48:3337-43. 2005
    ..A reinvestigation of the absolute configuration of 6beta-methoxytropinone proved the 6R configuration for the (+)-enantiomer...
  73. ncbi Early-onset Parkinson's disease in a Chinese population: 99mTc-TRODAT-1 SPECT, Parkin gene analysis and clinical study
    Woei Cherng Shyu
    Neuro Medical Scientific Center, Tzu Chi Buddhist General Hospital, Tzu Chi University, Hualien, Taiwan
    Parkinsonism Relat Disord 11:173-80. 2005
    ....
  74. ncbi Quantitation of dopamine transporter blockade by methylphenidate: first in vivo investigation using [123I]FP-CIT and a dedicated small animal SPECT
    Susanne Nikolaus
    Clinic of Nuclear Medicine, Heinrich Heine University, 40225, Dusseldorf, Germany
    Eur J Nucl Med Mol Imaging 32:308-13. 2005
    ....
  75. ncbi Differences in [99mTc]TRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's disease
    Randel L Swanson
    Division of Nuclear Medicine, 110 Donner Building, H U P, 3400 Spruce Street, Philadelphia, PA, 19104, USA
    Eur J Nucl Med Mol Imaging 32:302-7. 2005
    ..This study evaluated whether [99mTc]TRODAT-1 binding to the dopamine transporter differentiates MSA from other movement disorders...
  76. ncbi Quantification analysis of 123I-IPT single photon emission computed tomography uptake in the striatum of parkinsonism with the standard magnetic resonance template
    Rahyeong Juh
    Department of Biomedical Engineering, The Catholic University of Korea College of Medicine, Seoul, Korea
    Psychiatry Clin Neurosci 60:18-28. 2006
    ....
  77. ncbi Clinical impact of correlative [123I]-FP-CIT brain imaging and neurological findings in suspect Parkinson's disease
    Eugenio Maria Covelli
    Dipartimento di Diagnostica per Immagini, AORN San Sebastiano, Caserta, Italy
    Radiol Med 108:417-25. 2004
    ..Here we report our experience in a general hospital setting using [(123)I]-FP-CIT SPECT to diagnose patients with suspect Parkinson's disease (PD)...
  78. ncbi Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes
    Ana M Catafau
    Institut de Recerca, Hospital de Sant Pau, Barcelona, Spain
    Mov Disord 19:1175-82. 2004
    ..Imaging increased confidence in diagnosis, leading to changes in clinical management in 72% of patients. Consequently, visual assessment of (123)I-Ioflupane SPECT may have a significant impact on the clinical management of CUPS patients...
  79. ncbi Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism
    Maren Carbon
    Center for Neurosciences, North Shore Long Island Jewish Research Institute, New York, NY 11030, USA
    Neuroimage 21:1497-507. 2004
    ..Despite minimal reductions in nigro-caudate input, PD patients demonstrate a loss of this coupling early in the disease...
  80. ncbi Quantification of dopamine transporters in the mouse brain using ultra-high resolution single-photon emission tomography
    Paul D Acton
    Department of Radiology, University of Pennsylvania, 3700 Market Street Room 305, Philadelphia, PA 19104, USA
    Eur J Nucl Med Mol Imaging 29:691-8. 2002
    ....
  81. ncbi Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease
    Wen J Hwang
    Department of Neurology, College of Medicine, National Cheng Kung University, 138 Sheng Li Road, Tainan 704, Taiwan
    J Nucl Med 45:207-13. 2004
    ..We studied the test and retest reproducibility of (99m)Tc-TRODAT-1 SPECT measures in patients with PD to assess the reliability of (99m)Tc-TRODAT-1 for longitudinal evaluation of the nigrostriatal dopaminergic function...
  82. ncbi 99mTc-TRODAT-1 imaging of multiple system atrophy
    Chin Song Lu
    First Department of Neurology, Chang Gung Memorial Hospital at Taipei, Taipei, Taiwan
    J Nucl Med 45:49-55. 2004
    ....
  83. ncbi Synthesis of iodinated 3beta-aryltropanes with selective binding to either the dopamine or serotonin transporters
    Huw M L Davies
    Department of Chemistry, State University of New York at Buffalo, 14260 3000, USA
    Bioorg Med Chem Lett 12:845-7. 2002
    ..Iodinated 3beta-aryltropanes functionalized appropriately at the 2beta-, 8- and aryl positions display selective binding to either the dopamine or serotonin transporters...
  84. ncbi Dopamine transporter concentration is reduced in asymptomatic Machado-Joseph disease gene carriers
    Tzu Chen Yen
    Department of Nuclear Medicine, Chang Gung Memorial Hospital at Lin kou and Kee long, Chang Gung University, Taiwan
    J Nucl Med 43:153-9. 2002
    ....
  85. ncbi Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations
    Hani T S Benamer
    Neurology Department, New Cross Hospital, Wolverhampton, United Kingdom
    Mov Disord 18:977-84. 2003
    ..When these clinical features are uncertain, or the patient fails clinical diagnostic criteria, testing for dopaminergic deficit with [(123)I]-FP-CIT SPECT may assist the diagnostic process...
  86. ncbi Dopamine transporter change in drug-naive schizophrenia: an imaging study with 99mTc-TRODAT-1
    Mei Chun Hsiao
    Department of Psychiatry, Chang Gung Memorial Hospital, Chang Gung University, School of Medicine, Taiwan, ROC
    Schizophr Res 65:39-46. 2003
    ..The findings also suggest that TRODAT SPECT may be a useful technique to measure dopamine transmission in the human brain and for understanding the pathophysiology of neuropsychiatric disorders...
  87. ncbi Alteration of the striatal dopaminergic system in human narcolepsy
    I Eisensehr
    Departments of Neurology, University of Munich, Germany
    Neurology 60:1817-9. 2003
    ..017) and correlated with the frequency of cataplectic and sleep attacks (R > or = 0.844, p < or = 0.017). The human striatal dopaminergic system is altered in vivo in narcolepsy/cataplexy...
  88. ncbi Role of dopamine transporter imaging in routine clinical practice
    Vicky Marshall
    Institute of Neurological Sciences, Glasgow, United Kingdom
    Mov Disord 18:1415-23. 2003
    ....
  89. ncbi Synthesis and evaluation of iodine-123 labelled tricyclic tropanes as radioligands for the serotonin transporter
    Mitchell Quinlivan
    Department of Pharmacology, University of Sydney, NSW 2006, Australia
    Nucl Med Biol 30:741-6. 2003
    ..In view of these results [(123)I]1 and [(123)I]2 do not appear to be suitable radioligands for in vivo studies of the SERT...
  90. ncbi Clinical and [99mTc]TRODAT-1/[123I]IBZM SPECT imaging findings in dopa-responsive dystonia
    Wen Juh Hwang
    Department of Neurology, College of Medicine, National Cheng Kung University, Tainan, Taiwan
    Eur Neurol 51:26-9. 2004
    ..The patient showed a dramatic and sustained response to levodopa, and needed a smaller dose of levodopa for symptom control in the later course...
  91. ncbi A second-generation 99m technetium single photon emission computed tomography agent that provides in vivo images of the dopamine transporter in primate brain
    Peter C Meltzer
    Organix Inc, 240 Salem Street, Woburn, MA 01801, USA
    J Med Chem 46:3483-96. 2003
    ..s...
  92. ncbi Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc-TRODAT-1
    K Y Tzen
    Departments of Nuclear Medicine and Neurology, Chang Gung Memorial Hospital at Lin-Ko and Keelung, Taipei Medical Center and School of Medicine, Chang Gung University, Taiwan
    J Nucl Med 42:408-13. 2001
    ....
  93. ncbi Dopamine transporter binding in chronic manganese intoxication
    Chin Chang Huang
    Dept of Neurology, Chang Gung Memorial Hospital, 199, Tung Hwa North Road, Taipei, Taiwan
    J Neurol 250:1335-9. 2003
    ..In addition (99m)Tc-TRODAT-1 SPECT can provide a useful, convenient and inexpensive tool for differentiation between chronic manganism and PD...
  94. ncbi Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1
    K Van Laere
    Division of Nuclear Medicine, Leuven University Hospital and K U Leuven, Herestraat 49, 3000, Leuven, Belgium
    Eur J Nucl Med Mol Imaging 31:1119-27. 2004
    ....
  95. ncbi Imaging early-stage corticobasal degeneration with [99mTc]TRODAT-1 SPET
    Szu Chia Lai
    Movement Disorders Unit, First Department of Neurology, Chang Gung Memorial Hospital at Lin Ko, Taoyuan, Taiwan
    Nucl Med Commun 25:339-45. 2004
    ..2.1]oct-2-yl]methyl](2-mercaptoethyl)amino]ethyl]amino]ethanethiolato(3-)-N2,N2',S2,S2']oxo-[1R-(exo-exo)]-[99mTc]technetium ([99mTc]TRODAT-1) brain single-photon emission tomography (SPET)...
  96. ncbi Normal dopamine transporter binding in dopa responsive dystonia
    Chin Chang Huang
    Department of Neurology, Chang Gung Memorial Hospital, 199, Tung Hwa North Road, Taipei, Taiwan
    J Neurol 249:1016-20. 2002
    ..We conclude that a normal DAT in parkinsonian patients can differentiate DRD from YOPD. In addition, DAT with (99m)Tc-TRODAT-1 is a reliable and convenient tool to study the function of the presynaptic dopaminergic axonal terminals...
  97. ncbi L-Dopa-responsive Parkinson's syndrome in association with phenylketonuria: In vivo dopamine transporter and D2 receptor findings
    Andrew H Evans
    Reta Lila Weston Institute of Neurological Studies, University College London, United Kingdom
    Mov Disord 19:1232-6. 2004
    ..This combination of imaging findings indicates a possible upregulation of postsynaptic D2 receptors in the context of intact presynaptic dopamine nerve terminal density...
  98. ncbi Greater availability of brain dopamine transporters in major depression shown by [99m Tc]TRODAT-1 SPECT imaging
    David J Brunswick
    Depression Research Unit, Department of Radiology, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Am J Psychiatry 160:1836-41. 2003
    ..The present study was an examination of the availability of brain dopamine transporter sites in patients with major depression and in healthy comparison subjects...
  99. ncbi 99mTc-M-TRODAT is not superior to (99m)Tc-TRODAT-1 for the diagnosis of Parkinson's disease
    A Maes
    Eur J Nucl Med Mol Imaging 30:796-7. 2003
  100. ncbi Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study
    Yen Kuang Yang
    Department of Psychiatry, Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan 704, ROC
    Am J Psychiatry 161:1496-8. 2004
    ....
  101. ncbi Single photon emission computer tomography of dopamine transporters in monkeys and humans with 99mTc-TRODAT-1
    Ping Hu
    Department of Nuclear Medicine, First Affiliated Hospital, Sun Yat Sen University, Guangzhou 510080, China
    Chin Med J (Engl) 117:1056-9. 2004
    ..This study was designed to investigate the effects of imaging of dopamine transporters with 99mTc-TRODAT-1 in early diagnosis or differential diagnosis of Parkinson's disease...

Research Grants45

  1. CHEMICAL AND PHARMACOLOGICAL STUDIES OF COCAINE ANALOGS
    Alan Kozikowski; Fiscal Year: 2004
    ..Additionally, in pursuit of a methadone type of approach, we intend to identify one or more tropanes that exhibit partial cocaine-like properties in vivo, and, specifically, substances that may elicit some of the ..
  2. NET - Selective Ligands for the Treatment of Depression
    Kenneth Johnson; Fiscal Year: 2004
    ..Key words: depression, norepinephrine transporter (NET) inhibitors, conformationally constrained tricyclic tropanes, pharmacotherapy, PET imaging, chemical synthesis, behavioral testing.
  3. SYNTHESIS AND EVALUATION OF NOVEL COCAINE ANALOGS
    Huw Davies; Fiscal Year: 2002
    ..A novel synthetic strategy to tropanes based on the reaction between vinylcarbenoids and pyrroles has led to a series of extremely potent cocaine ..
  4. NOVEL PHARMACOTHERAPIES FOR COCAINE DEPENDENCE
    Frank Carroll; Fiscal Year: 2001
    ..An ideal candidate compound would not only have efficacy in the preclinical models but would be safe, orally active, and potent, would not show tolerance or sensitization, and if abusable, would be less so than cocaine. ..
  5. NOVEL PHARMACOTHERAPY FOR TREATMENT OF COCAINE ADDICTION
    Frank Carroll; Fiscal Year: 2008
    ..abstract_text> ..
  6. Design and Development of Pharmacotherapies for Treating Stimulant Abuse
    Frank Ivy Carroll; Fiscal Year: 2010
    ..3) To continue on a limited basis our development of selected 3-phenyltropane analogs as second-generation pharmacotherapies to treat cocaine addiction. ..
  7. COCAINE: A STUDY OF THE BIOCHEMICAL MECHANISM OF ACTION
    Frank Carroll; Fiscal Year: 2007
    ..abstract_text> ..
  8. Monoamine Transporters and Nonhman Primate Cocaine Use
    HEATHER KIMMEL; Fiscal Year: 2006
    ..The training experiences described will provide for the candidate's transition from a mentored scientist to an independent investigator. [unreadable] [unreadable] [unreadable] [unreadable]..
  9. Discovery of Novel Pharmacotherapies: Cocaine Dependence
    PETER MELTZER; Fiscal Year: 2008
    ..We will focus on three classes: 8-oxabicyclo[3,2,1]octanes (oxatropanes), 8-azabicyclo[3,2,1]octanes (tropanes) and pyrovalerone analogues...
  10. Chamomile therapy for generalized anxiety disorder
    Jay Amsterdam; Fiscal Year: 2006
    ....
  11. New imaging agents for studying gene expression
    HANK KUNG; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  12. Imaging vesicular monoamine transporters in the brain
    HANK KUNG; Fiscal Year: 2006
    ..Michael Kilbourn, University of Michigan. Combining the strength of two laboratories will greatly enhance the chance of reaching the goals proposed in this project. ..
  13. Imaging agents of norepinephrine transporters
    HANK KUNG; Fiscal Year: 2007
    ..abstract_text> ..
  14. Black cohosh therapy for menopause-related anxiety
    Jay Amsterdam; Fiscal Year: 2006
    ..We hypothesize that Black Cohosh will result in superior QOL measures compared to placebo. ..
  15. NEW TC-99M LABELED BRAIN IMAGING AGENTS
    HANK KUNG; Fiscal Year: 2001
    ..If the novel DAT imaging agents are successfully developed, the new Tc-99m labeled imaging agents will be scientifically meaningful and clinically important for the diagnosis of Parkinson's disease. ..
  16. SEROTONIN RECEPTOR LIGANDS FOR SPECT IMAGING
    HANK KUNG; Fiscal Year: 2004
    ..The novel imaging agents may lead to simple and useful routine diagnostic procedures for various mental health diseases involving SERT in the brain. ..
  17. STN STIMULATION--DA TRANSPORTERS & OUTCOME IN PARKINSON'
    Andrew Newberg; Fiscal Year: 2004
    ..This study will provide that data while pursuing a long-term goal of developing a more effective and economical method for objectively assessing the outcome of an new treatment. ..
  18. SEROTONIN RECEPTOR LIGANDS FOR SPECT IMAGING
    HANK KUNG; Fiscal Year: 2001
    ..The novel imaging agents may lead to simple and useful routine diagnostic procedures for various mental health diseases involving SERT in the brain. ..
  19. Siemens Symbia T SPECT-CT Scanner
    Andrew Newberg; Fiscal Year: 2006
    ..Overall, this scanner will become a major tool for our present and future research programs with a focus on brain SPECT imaging, but also the potential to include many other types of studies. [unreadable] [unreadable]..
  20. NEW CNS DOPAMINE RECEPTOR IMAGING AGENTS
    HANK KUNG; Fiscal Year: 2002
    ....
  21. In vivo imaging agents targeting Tau aggregates
    HANK KUNG; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  22. SPECT Brain Imaging as a Biomarker of Major Depression
    Jay Amsterdam; Fiscal Year: 2007
    ..We will compare these results to measurements of striatal DAT levels in 22 non-depressed, healthy subjects studied under similar conditions with [99mTc]TRODAT-1 SPECT on two separate occasions 8 weeks apart. ..
  23. Gene expression associated with the CNS reinforcing act*
    ZACHARY RODD HENRICKS; Fiscal Year: 2003
    ..The results of the proposed project will provide valuable information on neuronal systems and receptors within the extended amygdala involved in mediating the rewarding properties of alcohol. ..
  24. NEW TC-99M LABELED BRAIN IMAGING AGENTS
    HANK KUNG; Fiscal Year: 2004
    ..If the novel DAT imaging agents are successfully developed, the new Tc-99m labeled imaging agents will be scientifically meaningful and clinically important for the diagnosis of Parkinson's disease. ..
  25. Combined Treatment for GAD
    Paul Crits Christoph; Fiscal Year: 2008
    ..Data analysis will focus on differential rate of change (mixed model analyses) for the two groups. If promising results are obtained for combined treatment, a larger more definitive trial will be planned. [unreadable] [unreadable]..
  26. DEPRESSION DIAGNOSIS AND TREATMENT IN PARKINSON DISEASE
    Daniel Weintraub; Fiscal Year: 2008
    ..abstract_text> ..
  27. Regulation of NMDA Receptors in Excitotoxicity by Calpain and FYN
    David Lynch; Fiscal Year: 2007
    ..abstract_text> ..
  28. Quantitative Simultaneous Dual Isotope SPECT
    Georges El Fakhri; Fiscal Year: 2008
    ..We expect that our approach will make quantitative simultaneous dualisotope imaging clinically feasible, and lead to earlier diagnosis and better monitoring of PD and to improved evaluation of suspected acute cardiac ischemia. ..
  29. Novel Delta Opioids: Analgesic Effects & Abuse Liability
    SIDNEY NEGUS; Fiscal Year: 2009
    ....
  30. Detection of Amyloid Plaques
    Gilles Tamagnan; Fiscal Year: 2008
    ..In this application we proposed to develop a selective compound to quantify these plaques in human. [unreadable] [unreadable] [unreadable] [unreadable]..
  31. Patient Feedback Effectiveness Study
    Paul Crits Christoph; Fiscal Year: 2008
    ..A collaborating clinical trial application for this test of PF is being submitted by John Rotrosen, M.D., from New York University, School of Medicine. [unreadable] [unreadable]..
  32. The Process of Group Therapy for Cocaine Dependence
    Paul Crits Christoph; Fiscal Year: 2007
    ..Statistical solutions for addressing such "rolling" groups have yet to be developed. Our second aim is to develop a new statistical approach to the analysis of data from "rolling" groups. [unreadable] [unreadable]..
  33. Indole Glyoxylamides Peripheral Benzodiazepine Receptor Radiotracers
    Gilles Tamagnan; Fiscal Year: 2007
    ..At the conclusion of this project period, we expect to have identified a radioligand suitable for imaging the PBR in NeuroAIDS, dementia and other diseases...
  34. PARAMETERS AND MECHANISMS OF COCAINE TOLERANCE
    George King; Fiscal Year: 2001
    ....
  35. NMDA RECEPTORS, PROTEIN KINASE C, AND EXCITOTOXICITY
    David Lynch; Fiscal Year: 2002
    ..This systematic approach should provide critical information on the complete mechanisms of control of NMDA receptors by PKC and their significance in physiologic and pathophysiologic processes. ..
  36. MicroCT for Imaging Small Animals
    Paul Acton; Fiscal Year: 2003
    ..In conclusion, a microCT system would provide essential structural data to complement functional SPECT data in small animals, and will greatly strengthen the quantitative aspects of this emerging molecular imaging technique. ..
  37. GABA Modulation of Cocaine & Heroin Self-Administration
    David Roberts; Fiscal Year: 2003
    ..The degree to which either IP or intracerebral injections of baclofen affect heroin self-administration will also be assessed. ..
  38. Piperidine Derivatives as Radiotracers for Serotonin Transporters
    Gilles Tamagnan; Fiscal Year: 2004
    ..abstract_text> ..
  39. A Novel VMAT 2 Radioligand for Imaging Parkinson's
    Gilles Tamagnan; Fiscal Year: 2004
    ..abstract_text> ..
  40. AZABICYCLONONANE SEROTONIN TRANSPORTER RADIOTRACERS
    Gilles Tamagnan; Fiscal Year: 2005
    ..The most promising candidates will be radiolabeled with radionuclides, F-18, or 1-123 as appropriate to the molecule, and evaluated by imaging in vivo in non-human primates in a dedicated PET or SPECT imaging device. ..
  41. NICOTINIC RECEPTORS IN MAMMALIAN INTRACARDIAC NEURONS
    Javier Cuevas; Fiscal Year: 2001
    ..An understanding of the properties and physiological role of the receptors is necessary to comprehend neural control of the heart. ..
  42. DEVELOPMENT OF PET AND SPECT LIGANDS FOR mGluR5 IMAGING
    Gilles Tamagnan; Fiscal Year: 2007
    ..abstract_text> ..
  43. COMMUNITY-FRIENDLY MANUAL GUIDED DRUG COUNSELING
    Paul Crits Christoph; Fiscal Year: 2004
    ..The data gathered from this treatment development project will inform the design of a subsequent larger study. ..
  44. Simultaneous dual isotope SPECT
    Paul Acton; Fiscal Year: 2001
    ....